Literature DB >> 25781366

Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease.

Gilles Boschetti1, Marc'harid Laidet2, Driffa Moussata2, Carmen Stefanescu3, Xavier Roblin4, Gildas Phelip2, Eddy Cotte5, Guillaume Passot5, Yves Francois5, Jocelyne Drai6, Emilie Del Tedesco4, Yoram Bouhnik3, Bernard Flourie1, Stephane Nancey1.   

Abstract

OBJECTIVES: Fecal calprotectin (fCal) is widely used as marker of gut inflammation and is strongly associated with the severity of endoscopic lesions in Crohn's disease (CD). We analyzed the relationships between levels of fCal and high-sensitivity C-reactive protein (hsCRP) and the presence and severity of postoperative endoscopic recurrence in asymptomatic CD patients (Harvey-Bradshaw index≤3).
METHODS: Blood and fecal samples were collected in consecutive asymptomatic CD patients (Harvey-Bradshaw index 0.85 ± 0.19, mean ± s.e.m.) who had undergone an ileocolonic resection. hsCRP and fCal were measured and a routine ileocolonoscopy was performed within 18 months (median 7 months) from resection, to detect endoscopic recurrence according to the Rutgeerts score.
RESULTS: Eighty-six patients were included in this prospective multicenter observational cohort. fCal concentrations differed significantly in patients with endoscopic recurrence when compared with those in endoscopic remission (mean ± s.e.m.: 473 ± 78 μg/g vs. 115 ± 18 μg/g; P<0.0001). The area under the receiver operating characteristic (ROC) curve to discriminate between patients in endoscopic remission and recurrence was 0.86 for fCal and lower for hsCRP (0.70). The best cutoff point for fCal to distinguish between endoscopic remission and recurrence was 100 μg/g as determined by the ROC curve, and its sensitivity, specificity, positive and negative predictive values (NPVs), as well as overall accuracy were 95%, 54%, 69%, 93%, and 77%, respectively.
CONCLUSION: Measurement of fCal concentrations is a promising and useful tool for monitoring asymptomatic CD patients after ileocolonic resection. Taking into account the high NPV of fCal, a threshold below 100 μg/g could avoid systematic ileocolonoscopies in 30% of patients from this population.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25781366     DOI: 10.1038/ajg.2015.30

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  25 in total

Review 1.  Review article: the natural history of postoperative Crohn's disease recurrence.

Authors:  A Buisson; J-B Chevaux; P B Allen; G Bommelaer; L Peyrin-Biroulet
Journal:  Aliment Pharmacol Ther       Date:  2012-02-07       Impact factor: 8.171

2.  The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.

Authors:  A Orlando; I Modesto; F Castiglione; L Scala; D Scimeca; A Rispo; S Teresi; F Mocciaro; V Criscuoli; C Marrone; P Platania; T De Falco; S Maisano; N Nicoli; M Cottone
Journal:  Eur Rev Med Pharmacol Sci       Date:  2006 Jan-Feb       Impact factor: 3.507

Review 3.  Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.

Authors:  Uri Kopylov; Greg Rosenfeld; Brian Bressler; Ernest Seidman
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

4.  Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.

Authors:  Anders Lasson; Hans Strid; Lena Ohman; Stefan Isaksson; Mikael Olsson; Britt Rydström; Kjell-Arne Ung; Per-Ove Stotzer
Journal:  J Crohns Colitis       Date:  2014-01-11       Impact factor: 9.071

Review 5.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.

Authors:  James D Lewis
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

6.  A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.

Authors:  G D Naismith; L A Smith; S J E Barry; J I Munro; S Laird; K Rankin; A J Morris; J W Winter; D R Gaya
Journal:  Aliment Pharmacol Ther       Date:  2013-01-24       Impact factor: 8.171

7.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.

Authors:  Taina Sipponen; Erkki Savilahti; Kaija-Leena Kolho; Hannu Nuutinen; Ulla Turunen; Martti Färkkilä
Journal:  Inflamm Bowel Dis       Date:  2008-01       Impact factor: 5.325

8.  Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Michael Trummler; Stephan R Vavricka; Lukas E Bruegger; Frank Seibold
Journal:  Am J Gastroenterol       Date:  2009-09-15       Impact factor: 10.864

9.  Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study.

Authors:  Takayuki Yamamoto; Manabu Shiraki; Takuya Bamba; Satoru Umegae; Koichi Matsumoto
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

10.  Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.

Authors:  Stephane Nancey; Gilles Boschetti; Driffa Moussata; Eddy Cotte; Julie Peyras; Charlotte Cuerq; Julie Haybrard; Anne-Laure Charlois; Anne Mialon; Marion Chauvenet; Karine Stroeymeyt; Dominique Kaiserlian; Jocelyne Drai; Bernard Flourié
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

View more
  35 in total

1.  Can Fecal Biomarkers Detect Ileal Inflammation in Inflammatory Bowel Disease?

Authors:  Takayuki Yamamoto; Takahiro Shimoyama
Journal:  Am J Gastroenterol       Date:  2015-09       Impact factor: 10.864

2.  Levels of fecal calprotectin and the severity of postoperative patients with Crohn's disease.

Authors:  Cong Dai; Min Jiang; Ming-Jun Sun
Journal:  Am J Gastroenterol       Date:  2015-08       Impact factor: 10.864

3.  Response to Dai et al.

Authors:  Gilles Boschetti; Jocelyne Drai; Bernard Flourié; Stéphane Nancey
Journal:  Am J Gastroenterol       Date:  2015-08       Impact factor: 10.864

Review 4.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

5.  Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study.

Authors:  Takayuki Yamamoto; Takahiro Shimoyama; Satoru Umegae; Koichi Matsumoto
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

Review 6.  Utility of Biomarkers in the Management of Inflammatory Bowel Disease.

Authors:  Gursimran Kochhar; Bret Lashner
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

7.  Compliance with the faecal calprotectin test in patients with inflammatory bowel disease.

Authors:  Chloé Maréchal; Isabelle Aimone-Gastin; Cédric Baumann; Bastien Dirrenberger; Jean-Louis Guéant; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2017-02-06       Impact factor: 4.623

Review 8.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 9.  Approach to the Patient with Mild Crohn's Disease: a 2016 Update.

Authors:  Frank I Scott; Gary R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2016-09

Review 10.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.